Akela Pharma repeating Fentanyl inhalant safety study at FDA request

By: THE CANADIAN PRESS MONTREAL - Akela Pharma Inc. (TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S. Food and Drug Administration. Akela said Tuesday it remains on track to make regulatory submissions in 2010. Tamifun, a dry powder intended to carry drugs to treat pain and other ailments, will be tested by an American contract research organization. The studies are "expected to produce results allowing Akela to start the longer term safety arm of the Fentanyl (cancer pain drug) Taifun Phase 3 clinical trial in patients in the second quarter of 2009," the Montreal drug development company stated. "We are still on track to deliver the required toxicology studies results in time to allow us to meet our previously disclosed regulatory submission timelines of... [read full story]